S&P 500   5,005.77 (-0.11%)
DOW   37,986.71 (+0.56%)
QQQ   419.10 (-1.02%)
AAPL   165.24 (-1.08%)
MSFT   400.87 (-0.84%)
META   486.86 (-2.98%)
GOOGL   154.62 (-0.89%)
AMZN   176.16 (-1.71%)
TSLA   149.13 (-0.53%)
NVDA   817.73 (-3.42%)
AMD   150.76 (-2.79%)
NIO   3.86 (-3.50%)
BABA   68.70 (-0.26%)
T   16.39 (+0.37%)
F   12.09 (+0.25%)
MU   109.05 (-2.57%)
GE   150.94 (-1.31%)
CGC   7.55 (-3.58%)
DIS   111.91 (-0.46%)
AMC   3.15 (+7.88%)
PFE   25.56 (+0.67%)
PYPL   62.04 (-0.10%)
XOM   120.52 (+1.69%)
S&P 500   5,005.77 (-0.11%)
DOW   37,986.71 (+0.56%)
QQQ   419.10 (-1.02%)
AAPL   165.24 (-1.08%)
MSFT   400.87 (-0.84%)
META   486.86 (-2.98%)
GOOGL   154.62 (-0.89%)
AMZN   176.16 (-1.71%)
TSLA   149.13 (-0.53%)
NVDA   817.73 (-3.42%)
AMD   150.76 (-2.79%)
NIO   3.86 (-3.50%)
BABA   68.70 (-0.26%)
T   16.39 (+0.37%)
F   12.09 (+0.25%)
MU   109.05 (-2.57%)
GE   150.94 (-1.31%)
CGC   7.55 (-3.58%)
DIS   111.91 (-0.46%)
AMC   3.15 (+7.88%)
PFE   25.56 (+0.67%)
PYPL   62.04 (-0.10%)
XOM   120.52 (+1.69%)
S&P 500   5,005.77 (-0.11%)
DOW   37,986.71 (+0.56%)
QQQ   419.10 (-1.02%)
AAPL   165.24 (-1.08%)
MSFT   400.87 (-0.84%)
META   486.86 (-2.98%)
GOOGL   154.62 (-0.89%)
AMZN   176.16 (-1.71%)
TSLA   149.13 (-0.53%)
NVDA   817.73 (-3.42%)
AMD   150.76 (-2.79%)
NIO   3.86 (-3.50%)
BABA   68.70 (-0.26%)
T   16.39 (+0.37%)
F   12.09 (+0.25%)
MU   109.05 (-2.57%)
GE   150.94 (-1.31%)
CGC   7.55 (-3.58%)
DIS   111.91 (-0.46%)
AMC   3.15 (+7.88%)
PFE   25.56 (+0.67%)
PYPL   62.04 (-0.10%)
XOM   120.52 (+1.69%)
S&P 500   5,005.77 (-0.11%)
DOW   37,986.71 (+0.56%)
QQQ   419.10 (-1.02%)
AAPL   165.24 (-1.08%)
MSFT   400.87 (-0.84%)
META   486.86 (-2.98%)
GOOGL   154.62 (-0.89%)
AMZN   176.16 (-1.71%)
TSLA   149.13 (-0.53%)
NVDA   817.73 (-3.42%)
AMD   150.76 (-2.79%)
NIO   3.86 (-3.50%)
BABA   68.70 (-0.26%)
T   16.39 (+0.37%)
F   12.09 (+0.25%)
MU   109.05 (-2.57%)
GE   150.94 (-1.31%)
CGC   7.55 (-3.58%)
DIS   111.91 (-0.46%)
AMC   3.15 (+7.88%)
PFE   25.56 (+0.67%)
PYPL   62.04 (-0.10%)
XOM   120.52 (+1.69%)

Alder Biopharmaceuticals (ALDR) Short Interest Ratio & Short Volume

Notice: This company has been marked as potentially delisted and may not be actively trading.

Alder Biopharmaceuticals Short Interest Data

Current Short Volume
12,050,000 shares
Previous Short Volume
16,630,000 shares
Change Vs. Previous Month
-27.54%
Dollar Volume Sold Short
$227.44 million
Short Interest Ratio / Days to Cover
4.6
Last Record Date
September 30, 2019
Outstanding Shares
83,840,000 shares
Float Size
70,730,000 shares
Short Percent of Float
17.04%
Today's Trading Volume
0 shares
Average Trading Volume
5,117,415 shares
Today's Volume Vs. Average
0%
cover of A Guide to High-Short-Interest Stocks and How to Trade Them ebook
Short Selling Alder Biopharmaceuticals ?

Sign up to receive the latest short interest report for Alder Biopharmaceuticals and its competitors with MarketBeat's FREE newsletter.

Skip Charts & View Short Interest History

ALDR Short Interest Over Time

ALDR Days to Cover Over Time

ALDR Percentage of Float Shorted Over Time

Alder Biopharmaceuticals Short Interest History

Report DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date
9/30/201912,050,000 shares $227.44 million -27.5%17.0%4.6 $18.88

ALDR Short Interest - Frequently Asked Questions

What is Alder Biopharmaceuticals' current short interest?

Short interest is the volume of Alder Biopharmaceuticals shares that have been sold short but have not yet been covered or closed out. As of September 30th, investors have sold 12,050,000 shares of ALDR short. 17.04% of Alder Biopharmaceuticals' shares are currently sold short. Learn More on Alder Biopharmaceuticals' current short interest.

What is a good short interest ratio for Alder Biopharmaceuticals?

The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. ALDR shares currently have a short interest ratio of 5.0. Learn More on Alder Biopharmaceuticals's short interest ratio.

What is a good short interest percentage for Alder Biopharmaceuticals?

Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 17.04% of Alder Biopharmaceuticals' floating shares are currently sold short.

Is Alder Biopharmaceuticals' short interest increasing or decreasing?

Alder Biopharmaceuticals saw a decline in short interest during the month of September. As of September 30th, there was short interest totaling 12,050,000 shares, a decline of 27.5% from the previous total of 16,630,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

What is Alder Biopharmaceuticals' float size?

Alder Biopharmaceuticals currently has issued a total of 83,840,000 shares. Some of Alder Biopharmaceuticals' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Alder Biopharmaceuticals currently has a public float of 70,730,000 shares.

How does Alder Biopharmaceuticals' short interest compare to its competitors?

17.04% of Alder Biopharmaceuticals' shares are currently sold short. Here is how the short interest of companies in the sector of "medical" compare to Alder Biopharmaceuticals: Taro Pharmaceutical Industries Ltd. (0.49%), Ardelyx, Inc. (15.05%), Supernus Pharmaceuticals, Inc. (9.20%), Edgewise Therapeutics, Inc. (9.11%), Agios Pharmaceuticals, Inc. (12.06%), Avadel Pharmaceuticals plc (11.47%), Protagonist Therapeutics, Inc. (5.90%), Dynavax Technologies Co. (13.73%), Amneal Pharmaceuticals, Inc. (2.17%), Harmony Biosciences Holdings, Inc. (20.65%),

Which stocks are the most shorted right now?

As of the most recent reporting period, the following stocks had the largest short interest positions: DISH Network Co. ($469.35 million), Alder Biopharmaceuticals Inc ($227.44 million), Levi Strauss & Co. ($117.34 million), DBV Technologies S.A. ($30.76 million), Sears Hometown and Outlet Stores Inc ($8.91 million), DryShips Inc. ($6.38 million), and Revolution Lighting Technologies, Inc. ($214,521.00). View all of the most shorted stocks.

What does it mean to sell short Alder Biopharmaceuticals stock?

Short selling ALDR is an investing strategy that aims to generate trading profit from Alder Biopharmaceuticals as its price is falling. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

How does a short squeeze work against Alder Biopharmaceuticals?

A short squeeze for Alder Biopharmaceuticals occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of ALDR, which in turn drives the price of the stock up even further.

How often is Alder Biopharmaceuticals' short interest reported?

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including ALDR, twice per month. The most recent reporting period available is September, 30 2019.



More Short Interest Resources from MarketBeat

This page (NASDAQ:ALDR) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners